STAT3 and head and neck squamous cell carcinoma: Interestingly, transcriptome analyses of HNSCC cell lines reveals that STAT1 and STAT3 activation enable aldo-keto reductase family 1 member C1 (AKR1C1)-induced resistance to cisplatin, which can be overcome by ruxolitinib treatment (12).